Olfaction and apathy in Parkinson's disease.

Parkinsonism Relat Disord

The Alpert Medical School at Brown University, 343 Lloyd ave, Providence, RI 02906, USA.

Published: February 2010

Background: Olfactory deficits are frequent among patients with idiopathic Parkinson's disease (PD). Additionally, apathy (as quantified by the Apathy Evaluation Scale), is more prevalent in PD patients compared to the general population. Olfactory impairment and apathy are associated with dysfunction in overlapping brain regions. Neuroimaging studies indicate that the anterior cingulate gyrus and medial orbitofrontal cortex are hypoactive in apathetic patients and are also involved in secondary olfactory processing. However, no study until this point has been published investigating whether there is any association between olfactory dysfunction and apathy in PD patients.

Methods: In our study seventy consecutive patients with PD took the Brief Smell Identification Test (B-SIT), completed the Apathy Evaluation Scale (AES) and were administered the Folstein Mini-Mental Status exam (MMSE).

Results: Apathetic PD patients performed poorly on the B-SIT compared with non-apathetic PD patients and olfactory impairment correlated with apathy. The simultaneous disruption of olfaction and emotion in Parkinson's could be the result of disease pathology in brain regions involved in both olfactory and emotional processing and reinforces the idea that this link between olfaction and emotions may have clinical consequences.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.parkreldis.2009.09.004DOI Listing

Publication Analysis

Top Keywords

parkinson's disease
8
apathy evaluation
8
evaluation scale
8
olfactory impairment
8
brain regions
8
apathetic patients
8
olfactory
6
patients
6
apathy
6
olfaction apathy
4

Similar Publications

Searching for new drugs to treat Alzheimer's disease dementia through multiple pathways.

World J Clin Cases

January 2025

Department of Neurology, Guizhou Medical University, Guiyang 550004, Guizhou Province, China.

Dementia is a group of diseases, including Alzheimer's disease (AD), vascular dementia, Lewy body dementia, frontotemporal dementia, Parkinson's disease dementia, metabolic dementia and toxic dementia. The treatment of dementia mainly includes symptomatic treatment by controlling the primary disease and accompanying symptoms, nutritional support therapy for repairing nerve cells, psychological auxiliary treatment, and treatment that improves cognitive function through drugs. Among them, drug therapy to improve cognitive function is important.

View Article and Find Full Text PDF

This study aimed to evaluate different combinations of three dietary supplements for potential additive or synergistic effects in an Parkinson's Disease model. The complex and diverse processes leading to neurodegeneration in each patient with a neurodegenerative disorder cannot be effectively addressed by a single medication. Instead, various combinations of potentially neuroprotective agents targeting different disease mechanisms simultaneously may show improved additive or synergistic efficacy in slowing the disease progression and allowing the agents to be utilized at lower doses to minimize side effects.

View Article and Find Full Text PDF

Targeting cardiolipin metabolism for Parkinson's disease therapy.

Metabol Open

December 2024

Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 75 Mikras Asias, Goudi, 11527, Athens, Greece.

View Article and Find Full Text PDF

Parkinson's disease (PD) is a neurodegenerative disorder that significantly impacts patients' quality of life. Managing PD requires accurate assessment of motor and non-motor symptoms, often complicated by the subjectivity in symptom reporting and the limited availability of neurologists. To address these challenges, commercial wearable devices have emerged to continuously monitor PD symptoms outside the clinical setting.

View Article and Find Full Text PDF

Background: Interest in wearable device use in Parkinson's disease (PD) has grown rapidly with many compelling studies supporting diagnostic and therapeutic uses. Concurrently, consumer devices have proliferated and their role in health and wellness has expanded. However, incorporation of consumer and medical wearable devices into medical care has in our experience been limited.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!